FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

8 results

imatinib mesylate
(IMATINIB MESYLATE)
Camber Pharmaceuticals, Inc.
Usage: This drug is indicated for the treatment of newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), blast crisis, and acute lymphoblastic leukemia (ALL) in adults and pediatrics, as well as for myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.
imatinib mesylate
(Imatinib Mesylate)
Chartwell RX, LLC
Usage: This drug is indicated for treatment of Philadelphia positive chronic myeloid leukemia (CML) in various phases, acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).
imatinib mesylate
(Imatinib Mesylate)
Apotex Corp
Usage: This drug is indicated for the treatment of newly diagnosed and resistant Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), various myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastro-intestinal stromal tumors (GIST).
imatinib mesylate
(Imatinib Mesylate)
BluePoint Laboratories
Usage: This drug is indicated for newly diagnosed or treatment-resistant Philadelphia chromosome positive chronic myeloid leukemia, acute lymphoblastic leukemia in adults and pediatrics, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors in adults.
imatinib mesylate
(imatinib mesylate)
Archis Pharma LLC
Usage: This drug is indicated for the treatment of newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), Ph+ CML in various stages post-interferon therapy, relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors.
imatinib mesylate
(imatinib mesylate)
Qilu Pharmaceutical Co., Ltd.
Usage: This drug is indicated for treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and various myelodysplastic/myeloproliferative diseases, among other conditions, including aggressive systemic mastocytosis and gastrointestinal stromal tumors.
imatinib mesylate
(imatinib)
Mylan Pharmaceuticals Inc.
Usage: This drug is indicated for the treatment of various conditions including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).
nucala
(mepolizumab)
GlaxoSmithKline LLC
Usage: NUCALA is indicated for the add-on maintenance treatment of severe asthma (ages 6+), chronic rhinosinusitis with nasal polyps (ages 18+), inadequate chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis in adults, and hypereosinophilic syndrome in patients aged 12 and older.

Medications for Hypereosinophilic Syndrome

imatinib mesylate

imatinib mesylate

imatinib mesylate

imatinib mesylate

imatinib mesylate

imatinib mesylate

imatinib mesylate

nucala